Paul O’Connor - Concepedia

Author

Paul O’Connor

St. Michael's Hospital

Also Known As

Aaron Miller, O'Connor, Paul, Paul G O'Connor, Paul G. O'Connor, Paul O'Connor, Paul O’Connor, Paul O′Connor

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

St. Michael's Hospital University Hospital of Basel Rutgers New Jersey Medical School Heinrich Heine University Düsseldorf Rutgers, The State University of New Jersey

About

Paul O’Connor is an author at St. Michael's Hospital specializing in medicine, multiple sclerosis, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	754
2	Health Sciences	1	1	14
3	Public Health	1	1	10
4	Clinical Nutrition	1	1	14
5	Health Policy	1	1	10

Paul O’Connor

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, The Lancet Neurology Relapsing-remitting Multiple SclerosisNeurological DisorderMulticentre StudyImmunologyClinical Trials	2009	402
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial Patrick Vermersch, Anna Członkowska, Luigi ME Grimaldi, Multiple Sclerosis Journal	2013	348
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study V. Devonshire, Eva Havrdová, Ernst W. Radue, The Lancet Neurology Placebo-controlled Freedoms StudyDisease ProgressionNeurological DisorderDisabilityClinical Trials	2012	180
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b Kathryn C. Fitzgerald, Kassandra L. Munger, Karl Köchert, JAMA Neurology	2015	165
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis Catherine M. Dalton, Katherine Miszkiel, Gareth J. Barker, Journal of Neurology Neurobiology Of DiseaseT1 Hypointense LesionsNeurological DisorderMedicineImmunology	2004	126
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis Hans Hartung, Lawrence Steinman, Douglas S. Goodin, JAMA Neurology	2013	37
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis Xavier Montalbán, Giancarlo Comi, Jack P. Antel, Journal of Neurology Disease ProgressionNeurological DisorderClinical TrialsExtension StudyNeurology	2015	22
Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis Samantha Kimball, Jodie Burton, Paul O’Connor, Clinical Biochemistry UrologyCalcium SupplementationMetabolic Bone DiseaseMedicineClinical Nutrition	2011	14
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study Marcelo Kremenchutzky, Paul O’Connor, Reinhard Hohlfeld, Multiple Sclerosis and Related Disorders	2013	13
Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations William R. Garnett, Thomas D Gilbert, Paul O’Connor Clinical Therapeutics Pharmacoeconomic AnalysisAvailable Carbamazepine FormulationsHealthcare ValueHealth PolicyHealth Economics	2005	10

Page 1